Related Experiment Video

Updated: Jun 22, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

mTOR signaling pathway is a target for the treatment of colorectal cancer

Yan-Jie Zhang1, Qiang Dai, Dan-Feng Sun

  • 1Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine Renji Hospital, Shanghai, China.

Annals of Surgical Oncology
|June 12, 2009
PubMed
Abstract

Insights

Targeted inhibition of the mTOR signaling pathway, a key factor in tumorigenesis, shows promise for treating human colorectal cancer (CRC). Silencing mTOR significantly reduced cell growth in both laboratory and animal models, suggesting a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The role of mTOR signaling in human colorectal cancer (CRC) tumorigenesis requires further elucidation.
  • mTOR signaling is implicated in cancer development, but its specific involvement in CRC progression is not fully understood.

Purpose of the Study:

  • To investigate the distribution of mTOR signaling components in CRC and adenomas.
  • To evaluate the therapeutic potential of inhibiting mTOR in CRC.

Main Methods:

  • Immunohistochemical analysis of mTOR, p70s6 K, and 4EBP1 in human CRC and adenoma tissues.
  • In vitro studies using siRNA to inhibit mTOR in CRC cell lines (HCT116, SW480), assessing cell viability, cell cycle, and apoptosis.
  • In vivo evaluation in a CRC xenograft mouse model treated with mTOR siRNA, monitoring tumor volume, signaling activity, and apoptosis.

Main Results:

  • mTOR signaling components were highly activated in CRC and high-grade intraepithelial neoplasia (HIN) adenomas.
  • Activation intensity correlated with tumor infiltration depth in CRC.
  • mTOR inhibition via siRNA significantly reduced CRC cell growth both in vitro and in vivo.

Conclusions:

  • mTOR signaling is linked to clinical pathological features of human CRC.
  • siRNA-mediated silencing of mTOR presents a potential novel therapeutic strategy for CRC.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...